169 related articles for article (PubMed ID: 28840942)
1. Hemolysis related to intravenous immunoglobulins is dependent on the presence of anti-blood group A and B antibodies and individual susceptibility.
Mielke O; Fontana S; Goranova-Marinova V; Shebl A; Spycher MO; Wymann S; Durn BL; Lawo JP; Hubsch A; Salama A
Transfusion; 2017 Nov; 57(11):2629-2638. PubMed ID: 28840942
[TBL] [Abstract][Full Text] [Related]
2. Acute hemolysis after intravenous immunoglobulin amid host factors of ABO-mismatched bone marrow transplantation, inflammation, and activated mononuclear phagocytes.
Michelis FV; Branch DR; Scovell I; Bloch E; Pendergrast J; Lipton JH; Cserti-Gazdewich CM
Transfusion; 2014 Mar; 54(3):681-90. PubMed ID: 23829192
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial of anti-D immunoglobulin versus low-dose intravenous immunoglobulin in the treatment of childhood chronic idiopathic thrombocytopenic purpura.
El Alfy MS; Mokhtar GM; El-Laboudy MA; Khalifa AS
Acta Haematol; 2006; 115(1-2):46-52. PubMed ID: 16424649
[TBL] [Abstract][Full Text] [Related]
4. A prospective observational study of the incidence, natural history, and risk factors for intravenous immunoglobulin-mediated hemolysis.
Pendergrast J; Armali C; Callum J; Cserti-Gazdewich C; Jiwajee A; Lieberman L; Lau W; Lin Y; Parmar N; Pavenski K; Riden LS; Shehata N; Willie-Ramharack K; Tomlinson G; Tong TN; Binnington B; Branch DR;
Transfusion; 2021 Apr; 61(4):1053-1063. PubMed ID: 33433931
[TBL] [Abstract][Full Text] [Related]
5. Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients.
Kahwaji J; Barker E; Pepkowitz S; Klapper E; Villicana R; Peng A; Chang R; Jordan SC; Vo AA
Clin J Am Soc Nephrol; 2009 Dec; 4(12):1993-7. PubMed ID: 19833910
[TBL] [Abstract][Full Text] [Related]
6. Haemolysis after treatment with intravenous immunoglobulin due to anti-A.
Morgan S; Sorensen P; Vercellotti G; Zantek ND
Transfus Med; 2011 Aug; 21(4):267-70. PubMed ID: 21605202
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic plasma exchange as a therapeutic modality for the treatment of IVIG complications.
Welsh KJ; Bai Y
J Clin Apher; 2015 Dec; 30(6):371-4. PubMed ID: 26123478
[TBL] [Abstract][Full Text] [Related]
8. Isoagglutinin-reduced immunoglobulin retains efficacy in mouse models of immune thrombocytopenia and rheumatoid arthritis and is less likely to cause intravenous immunoglobulin-associated hemolysis.
Cen SY; Branch DR
Transfusion; 2020 Feb; 60(2):250-255. PubMed ID: 31837028
[TBL] [Abstract][Full Text] [Related]
9. Pathogenesis and mechanisms of antibody-mediated hemolysis.
Flegel WA
Transfusion; 2015 Jul; 55 Suppl 2(0):S47-58. PubMed ID: 26174897
[TBL] [Abstract][Full Text] [Related]
10. Association of hemolysis with high dose intravenous immunoglobulin therapy in pediatric patients: An open-label prospective trial.
Akman AO; Kara FK; Koksal T; Cakir BC; Karagol C; Sayli T
Transfus Apher Sci; 2017 Aug; 56(4):531-534. PubMed ID: 28818402
[TBL] [Abstract][Full Text] [Related]
11. Possible mechanisms for intravenous immunoglobulin-associated hemolysis: clues obtained from review of clinical case reports.
Padmore R
Transfusion; 2015 Jul; 55 Suppl 2():S59-64. PubMed ID: 26174898
[TBL] [Abstract][Full Text] [Related]
12. Hemolytic adverse effects of intravenous immunoglobulin: modeling predicts risk reduction with anti-A/B immunoaffinity chromatography and to a lesser extent with anti-A donor screening.
Mallick R; Hubsch A; Barnes DG
Transfusion; 2018 Dec; 58(12):2752-2756. PubMed ID: 30284263
[TBL] [Abstract][Full Text] [Related]
13. Blood group A mothers are more likely to develop anemia during antenatal intravenous immunoglobulin treatment of fetal and neonatal alloimmune thrombocytopenia.
Lakkaraja M; Jin JC; Manotas KC; Vinograd CA; Ferd P; Gabor J; Wissert M; Berkowitz RL; McFarland JG; Bussel JB
Transfusion; 2016 Oct; 56(10):2449-2454. PubMed ID: 27611703
[TBL] [Abstract][Full Text] [Related]
14. Intravenous immunoglobulin-related hemolysis in patients treated for Kawasaki disease.
Luban NL; Wong EC; Henrich Lobo R; Pary P; Duke S
Transfusion; 2015 Jul; 55 Suppl 2():S90-4. PubMed ID: 26174904
[TBL] [Abstract][Full Text] [Related]
15. Hemolytic events associated with intravenous immune globulin therapy: a qualitative analysis of 263 cases reported to four manufacturers between 2003 and 2012.
Berg R; Shebl A; Kimber MC; Abraham M; Schreiber GB
Transfusion; 2015 Jul; 55 Suppl 2():S36-46. PubMed ID: 26174896
[TBL] [Abstract][Full Text] [Related]
16. The role of isoagglutinins in intravenous immunoglobulin-related hemolysis.
Bellac CL; Hottiger T; Jutzi MP; Bögli-Stuber K; Sänger M; Hanschmann KM; Keller-Stanislawski B; Funk MB
Transfusion; 2015 Jul; 55 Suppl 2():S13-22. PubMed ID: 26174892
[TBL] [Abstract][Full Text] [Related]
17. Specifications for anti-A and anti-B in intravenous immunoglobulin: history and rationale.
Thorpe SJ
Transfusion; 2015 Jul; 55 Suppl 2():S80-5. PubMed ID: 26174902
[TBL] [Abstract][Full Text] [Related]
18. The role of inflammation in intravenous immune globulin-mediated hemolysis.
Pendergrast J; Willie-Ramharack K; Sampson L; Laroche V; Branch DR
Transfusion; 2015 Jul; 55 Suppl 2():S65-73. PubMed ID: 26174900
[TBL] [Abstract][Full Text] [Related]
19. Massive intravascular haemolysis after high dose intravenous immunoglobulin therapy.
Mohamed M; Bates G; Eastley B
Br J Haematol; 2013 Mar; 160(5):570. PubMed ID: 23294261
[No Abstract] [Full Text] [Related]
20. High-dose intravenous immunoglobulin is strongly associated with hemolytic anemia in patients with Kawasaki disease.
Nolan BE; Wang Y; Pary PP; Luban NLC; Wong ECC; Ronis T
Transfusion; 2018 Nov; 58(11):2564-2571. PubMed ID: 30265742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
